Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted covera...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-10-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/32/170/230117.full |
| _version_ | 1797368430952710144 |
|---|---|
| author | Antoní Torres Alona Kuraieva Gregory G. Stone Catia Cillóniz |
| author_facet | Antoní Torres Alona Kuraieva Gregory G. Stone Catia Cillóniz |
| author_sort | Antoní Torres |
| collection | DOAJ |
| description | Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has in vitro activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema. |
| first_indexed | 2024-03-08T17:32:22Z |
| format | Article |
| id | doaj.art-0e4c1d50bce245bda4e63deb127ddc71 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-03-08T17:32:22Z |
| publishDate | 2023-10-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-0e4c1d50bce245bda4e63deb127ddc712024-01-02T14:19:48ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172023-10-013217010.1183/16000617.0117-20230117-2023Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumoniaAntoní Torres0Alona Kuraieva1Gregory G. Stone2Catia Cillóniz3 Dept of Pulmonology, Hospital Clinic, University of Barcelona, IDIBAPS, ICREA, CIBERES, Barcelona, Spain Pfizer, New York, NY, USA Pfizer, Groton, CT, USA Dept of Pulmonology, Hospital Clinic, University of Barcelona, IDIBAPS, ICREA, CIBERES, Barcelona, Spain Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has in vitro activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema.http://err.ersjournals.com/content/32/170/230117.full |
| spellingShingle | Antoní Torres Alona Kuraieva Gregory G. Stone Catia Cillóniz Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia European Respiratory Review |
| title | Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia |
| title_full | Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia |
| title_fullStr | Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia |
| title_full_unstemmed | Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia |
| title_short | Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia |
| title_sort | systematic review of ceftaroline fosamil in the management of patients with methicillin resistant staphylococcus aureus pneumonia |
| url | http://err.ersjournals.com/content/32/170/230117.full |
| work_keys_str_mv | AT antonitorres systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT alonakuraieva systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT gregorygstone systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT catiacilloniz systematicreviewofceftarolinefosamilinthemanagementofpatientswithmethicillinresistantstaphylococcusaureuspneumonia |